Cas No.: | 1561902-73-5 |
Chemical Name: | 5,5'-(1-(3-(azacyclotridecan-1-yl)propyl)-1H-pyrrole-3,4-diyl)bis(3-nitrobenzene-1,2-diol) |
Synonyms: | ICSN-3250 |
SMILES: | N(CCCN1CCCCCCCCCCCC1)1C=C(C2C=C(O)C(O)=C([N+]([O-])=O)C=2)C(C2C=C(O)C(O)=C([N+]([O-])=O)C=2)=C1 |
Formula: | C31H40N4O8 |
M.Wt: | 596.681 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors; ICSN3250 is not a kinase inhibitor of mTOR, competes with and displaces phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity; displays no inhibitory capacity towards PI3Kα, β, γ, or δ; inhibits mTORC1 by following an unprecedented mechanism that involved its competition with PA at the FRB domain of mTOR to overcome the TSC negative regulation of mTORC1; ICSN3250 specifically targets cancer cells both in vitro and ex vivo. |